Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries-Reference-Cited by-同舟云学术

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries

Published:2023-01-12 Issue:2 Volume:10 Page:433-445
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Taylor Peter C.^ORCID,Gonzalez Yuri Sanchez^ORCID,Clark Ryan^ORCID,Faccin Freddy^ORCID,Howell Oliver^ORCID

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-022-00526-w.pdf

Reference35 articles.

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

2. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.

3. Silva-Fernández L, Macía-Villa C, Seoane-Mato D, Cortés-Verdú R, Romero-Pérez A, Quevedo-Vila V, et al. The prevalence of rheumatoid arthritis in Spain. Sci Rep. 2020;10(1):21551.

4. Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–30.

5. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn´s Disease;Patient Preference and Adherence;2024-06

2. Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast];Open Access Rheumatology: Research and Reviews;2023-10